CARA
Price
$4.65
Change
+$0.05 (+1.09%)
Updated
Jan 17 closing price
Capitalization
21.26M
38 days until earnings call
INTS
Price
$2.76
Change
-$0.01 (-0.36%)
Updated
Jan 17 closing price
Capitalization
41.69M
53 days until earnings call
Ad is loading...

CARA vs INTS

Header iconCARA vs INTS Comparison
Open Charts CARA vs INTSBanner chart's image
Cara Therapeutics
Price$4.65
Change+$0.05 (+1.09%)
Volume$11.27K
Capitalization21.26M
Intensity Therapeutics
Price$2.76
Change-$0.01 (-0.36%)
Volume$27.02K
Capitalization41.69M
CARA vs INTS Comparison Chart
Loading...
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CARA vs. INTS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CARA is a Hold and INTS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CARA: $4.65 vs. INTS: $2.76)
Brand notoriety: CARA and INTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CARA: 7% vs. INTS: 63%
Market capitalization -- CARA: $21.26M vs. INTS: $41.69M
CARA [@Biotechnology] is valued at $21.26M. INTS’s [@Biotechnology] market capitalization is $41.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CARA’s FA Score shows that 0 FA rating(s) are green whileINTS’s FA Score has 0 green FA rating(s).

  • CARA’s FA Score: 0 green, 5 red.
  • INTS’s FA Score: 0 green, 5 red.
According to our system of comparison, CARA is a better buy in the long-term than INTS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CARA’s TA Score shows that 2 TA indicator(s) are bullish while INTS’s TA Score has 4 bullish TA indicator(s).

  • CARA’s TA Score: 2 bullish, 4 bearish.
  • INTS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, INTS is a better buy in the short-term than CARA.

Price Growth

CARA (@Biotechnology) experienced а -2.11% price change this week, while INTS (@Biotechnology) price change was +28.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CARA is expected to report earnings on Feb 26, 2025.

INTS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INTS($41.7M) has a higher market cap than CARA($21.3M). INTS YTD gains are higher at: 56.818 vs. CARA (-24.020). INTS has higher annual earnings (EBITDA): -16.26M vs. CARA (-88.8M). INTS has less debt than CARA: INTS (145K) vs CARA (3.42M). CARA has higher revenues than INTS: CARA (8.69M) vs INTS (0).
CARAINTSCARA / INTS
Capitalization21.3M41.7M51%
EBITDA-88.8M-16.26M546%
Gain YTD-24.02056.818-42%
P/E RatioN/AN/A-
Revenue8.69M0-
Total CashN/A2.78M-
Total Debt3.42M145K2,357%
FUNDAMENTALS RATINGS
CARA: Fundamental Ratings
CARA
OUTLOOK RATING
1..100
95
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CARAINTS
RSI
ODDS (%)
Bearish Trend 11 days ago
90%
Bullish Trend 11 days ago
53%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 11 days ago
90%
Momentum
ODDS (%)
Bearish Trend 11 days ago
86%
Bullish Trend 11 days ago
42%
MACD
ODDS (%)
N/A
Bullish Trend 11 days ago
42%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
84%
Bullish Trend 11 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
75%
Bearish Trend 11 days ago
90%
Advances
ODDS (%)
Bullish Trend 26 days ago
81%
Bullish Trend 13 days ago
61%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
View a ticker or compare two or three
Ad is loading...
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPCX13.780.12
+0.88%
Goldman Sachs Large Cap Core C
ASVHX10.980.08
+0.73%
American Century Small Cap Value G
MNHCX25.510.15
+0.59%
Manning & Napier Pro-Blend Max Term L
NIOIX13.010.03
+0.23%
Neuberger Berman Intl Small Cap I
DHIAX17.160.02
+0.12%
Diamond Hill International Inv

CARA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CARA has been loosely correlated with CYCC. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CARA jumps, then CYCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARA
1D Price
Change %
CARA100%
+1.09%
CYCC - CARA
61%
Loosely correlated
+0.99%
CKPT - CARA
47%
Loosely correlated
-4.50%
GPCR - CARA
41%
Loosely correlated
+0.30%
AXON - CARA
37%
Loosely correlated
+1.37%
FBIO - CARA
32%
Poorly correlated
-2.09%
More

INTS and

Correlation & Price change

A.I.dvisor tells us that INTS and CARA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and CARA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-0.36%
CARA - INTS
30%
Poorly correlated
+1.09%
GBIO - INTS
28%
Poorly correlated
+0.18%
ACAD - INTS
28%
Poorly correlated
+0.29%
CCCC - INTS
27%
Poorly correlated
+2.07%
SYRE - INTS
26%
Poorly correlated
+0.34%
More